Heinz Sill
Overview
Explore the profile of Heinz Sill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
1887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wurm S, Waltersdorfer M, Loindl S, Moritz J, Herzog S, Bachmaier G, et al.
Wien Klin Wochenschr
. 2024 Nov;
PMID: 39527258
Background: Next-generation sequencing (NGS) has recently entered routine acute myeloid leukemia (AML) diagnostics. It is paramount for AML risk stratification and identification of molecular therapeutic targets. Most NGS feasibility and...
2.
Witalisz-Siepracka A, Denk C, Zdarsky B, Hofmann L, Edtmayer S, Harm T, et al.
Front Immunol
. 2024 Jul;
15:1374068.
PMID: 39034990
Acute myeloid leukemia (AML) is a heterogenous disease characterized by the clonal expansion of myeloid progenitor cells. Despite recent advancements in the treatment of AML, relapse still remains a significant...
3.
Edtmayer S, Witalisz-Siepracka A, Zdarsky B, Heindl K, Weiss S, Eder T, et al.
Cell Death Dis
. 2024 May;
15(5):369.
PMID: 38806478
Signal transducer and activator of transcription 3 (STAT3) is frequently overexpressed in patients with acute myeloid leukemia (AML). STAT3 exists in two distinct alternatively spliced isoforms, the full-length isoform STAT3α...
4.
Moritz J, Schwab A, Reinisch A, Zebisch A, Sill H, Wolfler A
Biomedicines
. 2024 Mar;
12(3).
PMID: 38540210
Acute myeloid leukemia (AML) is an aggressive malignant disease with a high relapse rate due to the persistence of chemoresistant cells. To some extent, these residual cells can be traced...
5.
Sconocchia T, Fosselteder J, Auinger L, Ozkaya E, Benezeder T, Lang M, et al.
Leukemia
. 2023 Sep;
37(11):2292-2296.
PMID: 37673974
No abstract available.
6.
Pleyer L, Vaisband M, Drost M, Pfeilstocker M, Stauder R, Heibl S, et al.
Am J Hematol
. 2023 Aug;
98(11):1685-1698.
PMID: 37548390
The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with...
7.
Fosselteder J, Pabst G, Sconocchia T, Schlacher A, Auinger L, Kashofer K, et al.
Leukemia
. 2023 Feb;
37(4):843-853.
PMID: 36813992
Calreticulin (CALR) mutations present the main oncogenic drivers in JAK2 wildtype (WT) myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where mutant (MUT) CALR is increasingly recognized as a suitable...
8.
Meszaros N, Lind K, Sehlke R, Vilagos B, Krall N, Vladimer G, et al.
Br J Haematol
. 2022 Nov;
200(3):e32-e36.
PMID: 36366863
No abstract available.
9.
Leisch M, Pfeilstocker M, Stauder R, Heibl S, Sill H, Girschikofsky M, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626063
Azacitidine is the treatment backbone for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia who are considered unfit for intensive chemotherapy. Detailed reports on adverse events in...
10.
Geissler K, Jager E, Barna A, Gurbisz M, Marschon R, Graf T, et al.
Eur J Haematol
. 2022 Mar;
109(1):50-57.
PMID: 35299281
Background: A multistep pathogenesis of myeloid leukemia including mutations in epigenetic, spliceosome, and signaling genes has been recently demonstrated in a preclinical model but is poorly validated in patients. Methods:...